day, welcome to the Accelerate Diagnostics Inc 2023 Q2 Results Conference Call. Today, all participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions during the session. Please note, this event is being recorded. I would now like to turn the conference over to Laura Pierson of Accelerate Diagnostics. Please go ahead. Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future, and those that are not historical facts. All forward-looking statements that are made during this conference call are subject to risks, uncertainties, and other factors that could cause our actual results to differ materially. These are discussed in greater detail in our annual report on Form 10-K for the year ended December 31st, 2022, and other reports we file with the SEC. It is my pleasure to now introduce the company's President and CEO, Jack Phillips. Thank you, Laura. Good afternoon, and welcome to our second quarter earnings call. Today's call will focus on our second quarter results and include several updates on our strategic priorities. My commentary will focus on our three strategic priorities. First, I would like to review our innovation advancements with our next-generation susceptibility platform, Wave. Our second priority is to continue to grow market share through our Becton Dickinson partnership with Pheno and our sample preparation instrument, Arc. Finally, continuing to build financial strength, which I will touch on closing out our debt restructuring transaction and reducing our cash burn. Before I discuss these important strategic priorities further, I'd like to hand it over to our Chief Financial Officer, David Patience, to review our preliminary second quarter financial results. David? Thank you, Jack. Good afternoon, everyone. In the second quarter, the U.S. contracted 13 new Pheno instruments. We ended the quarter with a revenue-generating installed base of 339 Pheno instruments and a backlog of 70 instruments pending implementation. Net sales were approximately $2.9 million in the second quarter and $5.7 million year to date. This compares to approximately $3.9 and $6.8 million for the same period in 2022. The decrease in revenues were driven by a few large capital deals in the prior period, which did not repeat in the current quarter. Cost of goods sold were $2.1 million and $3.9 million year to date, resulting in a gross margin of 27% for the quarter and 32% year to date. This compares to cost of goods sold of $2.8 million and $4.9 million, and gross margins of 28% for the prior period. The decline in cost of goods sold was driven by fewer Pheno capital instruments, as discussed, as well as a reduction in equity-based compensation. Selling, general, and administrative expenses for the quarter were $7.6 million and $17.7 million year to date. This compares to $11.5 million and $22.2 million for the prior period. SG&A expenses, excluding non-cash stock-based compensation, were $6.3 million for the quarter and $16.5 million year to date. This compared to $8.3 million and $16.5 million for the prior period. The decrease in SG&A expenses for the current quarter were due to lower employee-related expenses, while year-to-date figures included non-recurring debt restructuring-related transaction expenses. Research and development expense for the quarter was $5.8 million and $12.8 million year to date. This compared to $7.6 million and $13.6 million for the prior periods. R&D expenses, excluding non-cash stock-based compensation, was $5.6 million and $11.9 million year to date. This compares to $7.0 million and $12.7 million for the prior periods. The decrease in R&D expenses was primarily driven by reductions in consulting spend as our Wave program continued to advance through development. Our GAAP net loss was $26 million for the quarter and $42.8 million year to date, resulting in a net loss per share of $2.36 and $4.11, respectively. Please note, on July 11, we effected a 10-for-1 reverse stock split of the company's outstanding shares of common stock. All shares and per share amounts have been retroactively adjusted for all periods presented to reflect the reverse stock split. Our non-operating expenses for the quarter were approximately $13.4 million, which included several notable non-cash related expenses for our debt restructuring transaction. Our net loss from operations, excluding non-cash stock-based compensation expense, was $10.9 million for the quarter and $26.4 million year to date. Net cash used was $15.2 million for the quarter and $28.9 million year to date, excluding cash flows from financing. Notable drivers of increased cash burn for the quarter and year to date were professional and legal fees related to our debt restructuring transactions. We anticipate our quarterly burn to reduce in the third quarter and thereafter. We ended the quarter with cash and equivalents of $30.7 million. Now back to you, Jack. Thanks, David. Now turning to our strategic priorities: delivering innovation with our Wave platform, growing market share through our partnership with BD, and finally, building our financial strength. First, I will review the importance of our innovation with our next-generation susceptibility platform, Wave. Best to understand our overall market opportunity, it's important to understand the total available testing market. Wave will be performing antibiotic susceptibility testing on positive blood cultures, or PBC, and isolated colonies, or sometimes referred to as isolates. Positive blood cultures, which are taken directly from a PBC bottle, are approximately 5%-8% of any given lab's testing volume. While PBC samples are lower volume, these samples are arguably the most critical samples in microbiology because they provide actionable results for the patients who are in critical condition due to a bloodstream infection. Isolates, on the other hand, can be both high acuity and low acuity samples, and represent nearly all other antibiotic susceptibility testing within the lab. Isolates are microorganisms which come from any sample and are separated or isolated from clinical samples such as respiratory, GI, urine, just to name a few. Annually, there are over 130 susceptibility tests performed from isolated colonies and over 7 million tests from PBC samples globally. Leveraging our deep experience in rapid susceptibility testing, we worked with customers to develop our next generation platform, Wave, to build on our PBC testing menu and include the much higher volume segment of isolate testing on a single platform. The Wave system will offer a comprehensive test menu covering all susceptibility samples, catering to diverse hospital antibiotic formularies and incorporating essential features to optimize workflow across laboratories. With full random access for continuous sample loading, Wave scalability addresses the needs of various healthcare settings, from small community hospitals to large academic centers and reference labs. Speed is paramount in susceptibility testing, and Wave's swift results will establish a new standard for turnaround time, empowering clinicians to respond within the same shift. Moreover, Wave's competitive cost of goods sold ensures it will compete effectively with incumbent platforms, aligning with existing lab budgets. Over the past year, we have continued to validate Wave's critical product specifications with key clinical and lab stakeholders. Prospective customers confirmed our platform approach, rapid turnaround times enable same-shift results, and our planned extensive menu addresses formulary requirements. Our gram-negative PBC algorithms are near completion. We are running 1,000 Wave cards a week on our fleet of Alpha AST modules, with more than 100 million images taken to date to support algorithm development. Performance is meeting our expectations. Our algorithms comprehend not only growth metrics of microorganisms, but also morphological contributions to each drug response, enabled by our proprietary dynamic holographic imaging. This approach enables early and real-time identification of resistant clones, which ensures both accurate and timely susceptibility test reporting. We achieve this with our technology's ability to focus on a single cell morphology in real time. These exciting program developments confirm Wave's ability to deliver comprehensive susceptibility testing in microbiology labs. Our recent progress with the Wave program reinforces our commitment to providing preclinical study readouts by year-end, followed closely by the initiation of clinical studies for subsequent FDA submissions. Turning to our second strategic priority, which is to continue to grow market share through our Becton Dickinson partnership. We continue to track our progress through two key metrics: commercial reach, which is tracked by the number of new sales opportunities into the funnel, and sales effectiveness, which is measured by funnel progression and velocity to eventual close. The U.S. commercial teams continue to integrate, as evidenced by the growth of the combined portfolio's new opportunities. Thus, commercial reach continues to be a strength, with consistent growth of new opportunities coming into the funnel. After just seven months into the partnership being launched, we are pleased with the progress of the BD commercial team's ability to position Pheno within the breadth of a combined bloodstream infection portfolio. Additionally, in the second quarter, we saw more opportunities advance further in the sales funnel. Sales velocity is notably increasing, with a couple of account closes in less than 90 days of the opportunity being created. We are encouraged to see BD's strong relationships being leveraged into quick wins for the partnership. The 13 newly contracted Phenos for the quarter was our strongest quarter since 2021, we continue to expect to deliver incremental quarterly placement growth. As mentioned in our prior quarter earnings calls, our EMEA commercial effort is more complicated given tender-driven markets, which has led to a delay. We continue to work collectively to roll out a simplified contract, which will allow BD to represent the full product portfolio in tenders. This approach should improve both contracting and adoption rates, as it will allow us to win not only new tender opportunities, but also be added to existing tenders. We remain enthusiastic about our automated Arc system, which rapidly cleans up PBC samples to enable direct MALDI-TOF microbial identification to eliminate the overnight culture step. We are currently seeing growing interest in the EMEA market through our BD partnership. In the US, we are poised to initiate clinical trials in the short term to ensure a Class II, 510(k) system is launched next year. In summary, the BD partnership is progressing, and we remain encouraged by the strong sales metrics and improved closes in the quarter. We expect this momentum to translate into increased placements and future revenues as we continue to bring new customers live. Lastly, on our financial strength, we announced the closing of our debt restructuring late in the second quarter, which allowed us to extend our convertible debt maturities out 3.5 years. It simplified our capital structure and brought in new capital. As discussed in our prior quarter, we are focusing on improving operational efficiency and further reducing cash burn. I would now be happy to answer questions from our analysts, and should others on the call have any questions not addressed, we would welcome you to send these questions or request a follow-up meeting to investors at axdx.com. Thank you. Thank you. We will now begin the question and answer session. Today's first question comes from Alex Nowak with Craig-Hallum. Please proceed. Hey, good afternoon, everyone. This is Conner Chamberlain on for Alex. Thanks for taking my questions. First off, can you give us the latest update on the pathway for ARC approval? I'm assuming a De Novo 510(k), but... Feeding off that, what are some studies you need to run with this as well? Yeah. Hi, Conner. Thanks for the question. Sure, sure thing. We are well underway with our planning for a clinical trial for ARC in the U.S.. The clinical trial hasn't started yet, but we're in the process of identifying the sites. We have a clinical trial partner in place to help us manage that clinical trial as well. In addition, just over the past couple weeks, I've reviewed the clinical trial design as well, and that we're ready to move forward with. Things are coming into place fairly rapidly with everything we need to do to basically embark on a clinical trial. We expect the clinical trial to be, frankly, pretty straightforward, given, you know, given what we're, you know, what we're actually going to be, you know, doing the clinical study on, which is downstream MALDI. We're still looking to submit a successful clinical study, and then a successful submission to the FDA by year-end and, you know, hopefully a rapid approval shortly thereafter. Awesome. Very helpful. What's the pathway for Wave approval? What clinical studies do we need on that, and do you have any timeline on that as well? Yeah, sure. On Wave, you know, as, as we mentioned in our prepared remarks, we're making really good progress in many in many areas with regard to Wave. As we get closer to a clinical trial, you know, first thing I would mention is we're, we're first gonna be proceeding forward with a preclinical study or trial ahead of that, just to confirm the results that we're seeing right now in the studies that we're doing relative to algorithm development. That's happening, you know, the preclinical study, we expect to happen before the end of the year, be complete with that. We will be. We also have, again, a partner already secured to help manage our clinical study. We expect that clinical study to start shortly thereafter, the preclinical study. The clinical trial, I should say, will start shortly thereafter, likely in Q1 of 2024 is what we're shooting for. It will be a gram-negative focus, positive blood culture study, and then we'll be preparing in parallel for a submission on positive blood culture, gram-positive, and then also isolates. As a reminder, the system will, for Wave, will do really, is set to do isolates as well as positive blood culture, and we'll be rapidly seeking to get approval for, for all those type of combinations. ... Excellent. Then just one more, can you give us an update on the competitive environment for these rapid or these rapid microbiology systems? You broke up a little bit there, but I think you said the competitive arena. Is that what you're talking about? Just an update on the competitive environment for these rapid microbiology systems. Sure. That's what I thought you said. Sure, no problem. I mean, where we're at right now, I mean, clearly, embedded with BD, and our partnership is going very well, selling a complete bloodstream infection solution from end-to-end, and that continues to go very well. The, the solution that we have with Pheno continues to resonate in the market, rapid, positive or rapid identification with AST, AST only, as well as ARC, not launched in the US, of course, but in Europe. That continues to resonate very well. Yes, as we expected, emerging competitors are coming. We've seen them in Europe a bit, not so much in the US, just because of clearance timelines. We're very confident in our menu. We're very confident in the 80-plus studies that we already have published on Pheno, the confidence that our current customers have in Pheno. While, I think competition overall is a very good thing for, for any market, actually, it will make us better, make us stronger, and, in essence, I think we're well, well suited, especially with our partnership with BD, to compete with the emerging competitors. Awesome. Got it. Oh, well, that's all I got. Thanks for taking my questions, guys. Thanks, Conner. The next question is from Andrew Brackmann, with William Blair. You may go ahead. Hey, everyone, this is Dustin on for Andrew. Thanks for taking our questions. First question on the BD partnership. Just wondering what the status is in cross-training of the sales team there, and how the synergies in the sales team there is translating into some reductions in operating expenses, and if those are tracking to your thoughts at the start of the partnership? Perfect. I'll take the first end of that and let David take the second part of the question around cash burn reductions and so forth. First of all, let me touch first on the US. We are fully trained, we fully trained the entire U.S. organization within BD. Just a reminder, I mean, Becton Dickinson is one of the largest microbiology and diagnostic companies in the world, so they have a lot of sales reps, a lot of marketing, regions, et cetera. It's, it's, it's a comprehensive organization. We've had very successful trainings in the US. We have all the marketing materials in their hands. We, we have ongoing training as well. We've done, you know, initial training, and then we're doing ongoing training on a regular basis out in the field. We have also online learning sessions as well, and overall going very well. In Europe, it's taken a bit longer, and it's just really because of the nature of Europe with the many countries, the many different languages, et cetera, et cetera. We've been training in Europe, and we're about complete in the initial training in Europe for most all the countries in the Wave one cycle that we'll be focused on, and that's complete. We also plan to do ongoing follow-up training in all those countries as well, as we come up to speed and start, start ramping up our efforts. But overall, again, I think the training's been going very well, not only for Pheno and ARC, but also the overarching strategy for BD, which is their bloodstream infection strategy that really focuses on a comprehensive solution for bloodstream infections across the entire continuum of care, from sample collection through blood culture, through identification, and then ultimately, rapid susceptibility with Pheno. All of that's coming together as well. That's new for the BD sales team, as well as Pheno. I got to say, we're, you know, we're really happy with... While it's taken a while to get it off the ground, we're really starting to see great activity. As I mentioned in some of the remarks, I mean, we've got really good activity going on. We definitely need to put more closes on the board, but we, you know, we had the best quarter we've had in quite a long time in Q2. We look, look for better quarters moving forward. Your second part of the question on the how is this doing relative to cash burn? I'll turn it over to David for that one. Yeah, as it relates to the cash burn and the reductions thereof in SG&A, about this time last year is when we announced a restructuring of our commercial organization in the United States to reflect the selling strategy we're gonna implement with BD. So with that, it would be, you know, a, a focused effort in, in the Accelerate commercial organization to support the commercial reach that BD brings, and to have Accelerate bring on the commercial and selling effectiveness to bring opportunities further and further into the funnel to close. So with that, those numbers were a bit muddied in the first quarter of this year due to SG&A-related expenses to the debt restructuring transaction. The debt restructuring transaction did close in the second quarter, but the accounting for those fees related to professional and legal fees of the debt restructuring went into debt and equity issuance costs. The year-to-date figures reflect legal and professional services from our transaction, but the second quarter figures are more cleaned, if you will, to give you a further run rate and then a non-cash stock-adjusted basis of that SG&A spend. Looking at the second quarter number is a cleaner way to look at it, and then understanding that these expenses are one-time, non-reoccurring to the transaction, give you kind of a forward-looking number that we're looking to operationally improve on a go-forward basis. With that, taking a step back, you know, having the transaction behind us and furthering the Wave development program allows us to lower our spend with third parties. Moving forward, we anticipate our cash burn to materially come down over just the next quarter, the rest of the year, as well as into 2024. Understood. Appreciate the color there. Second question, we've been hearing a lot from competitors on, on turnover at labs and hospitals in terms of staffing. Just wondering, is there any derivative impact to you guys and the conversations you're having with lab directors there, or you're not really exposed to that as much? Yeah, great point, and the answer is yes, we see this-- we see that as well. There's an incredible amount of turnover, post-COVID, within healthcare in general, and definitely in the laboratories. It's at both, both the staffing level, so, you know, the, the microbiologist and the other lab technicians, it's, it's there, and it's also at the management and senior management level. That is challenging for sure. It's definitely something that, it slows down go lives. We've had two go lives that did not go live in the quarter because of management change, and the key champions that were part of, you know, part of the Pheno or Accelerate implementation with us and BD, have changed, those are, you know, those are still going to be on track. It's just delayed because of a, a new microbiology manager or lab director, being, being replaced or, or leaving. We're seeing that turnover. I do expect it to settle down. I mean, that's what typically happens, and I expect it to get back to more normal. It's something that we continue to address. In some cases, it does create new opportunities for us as, you know, lab directors move from site to site, and they're, they're proponents of rapid susceptibility, and Pheno and BD, et cetera. Those are also positive examples to where this, where change within the laboratory can be good, and we've seen some of that as well, where we've seen change and new directors come in that, that really know the value of rapid susceptibility and, and Pheno, and, and we immediately have a sales opportunity overnight. I think it goes both ways, but it is definitely something that we continue to address on a daily basis out in the field. Understood. Last question for us, just on the reintroduction of ARC, when that eventually comes to the U.S. market, how impactful do you think this could be on eventually driving momentum with BD, once this occurs? I mean, we're very bullish on the value proposition for ARC. So is Becton Dickinson, as well as, you know, other people that are focused in the MALDI sector. I mean, it's a. Just a reminder of what ARC is, ARC addresses a real unmet medical need within microbiology. There are about, there's thousands, I mean, over 10,000 MALDI platforms placed globally in laboratories today. It was a great, great advancement in technology and microbiology for a number of reasons. It's very cost-effective to run MALDI. It's a, it's a very, very wide range menu that MALDI produces, fairly easy to use, good results. So it's a, it's well-planted in microbiology. One of the drawbacks, it's been a, a real drawback from, from day one, is if you want to run, you know, if you want to run a rapid identification off of MALDI, that's just not possible in the current state without doing something different, because today, MALDI identification is run through a first performing an isolated colony and, and then spotting, spotting MALDI from there. What ARC does is ARC automates that entire process in two steps in about one hour, and allows you to then plate, plate the MALDI platform and get your result in the same shift. You know, when we came on the market in the US, we saw immediate, you know, interest uptake. You know, we had significant number of evaluations signed up, and, and that's only, you know, while the-- as we've talked, I mean, we're going back and getting a, a Class II, a Class II claim from the FDA. In the end, that will, you know, that will actually be that, that will be a favorable feature to have, a favorable claim to have a valid-- more of a validated platform, out in the market. The unfortunate thing, it just takes time to go through the clinical trials, as I mentioned earlier here, and then ultimately through FDA clearance. We are very excited about this, and, and we believe it's gonna be a good alternative for customers globally, to, to, really that are seeking a rapid identification off of MALDI. Understood. Thanks for taking our questions. This concludes our question-and-answer session. I would now like to turn the conference back over to Mr. Jack Phillips for any closing remarks. Yeah, thank, thanks. I appreciate it, Chris. Just a couple of things from my side in closing. First of all, thanks for dialing into our Q2 earnings call. It's greatly appreciated. Just a couple of things to highlight as we think about our strategic imperatives that we've highlighted today. First of all, our next generation platform, Wave, continues to-- we continue to make really good progress and hit our milestones on this platform. It is a platform that will open up a much, much larger market within microbiology. It will be the platform that will perform isolates, which, as I mentioned, is over 100 million tests globally. That's gonna be very important and a very important segment for us to address. Things continue to go very well with Wave, and as I mentioned, we will not only have Wave isolates on the platform, we'll also have positive blood on a single platform, random access, scalable. This platform will fit in community hospitals, but also reference labs and regional, regional labs as well as academic centers. It's a truly a scalable platform that's so important, you know, as you look at, as you look at the entire health system. More to come there. Finally, we continue to see very good quality performance on our initial studies that we've been going through. Over 100 million images taken now off of our 15 alpha units that are running day and night in our laboratory here in Tucson. The second thing I'd say with our partnership with Becton Dickinson and our, our commercial effectiveness. You know, as I mentioned, very large, very large microbiology company in BD. They're a terrific partner, and it's taken, taken us a while to get through training, to get reps comfortable and confident in selling rapid identification and susceptibility. We're getting there. Every day is a better day out in the field and in the market. Our reach continues to grow, and that means new accounts coming into the funnel continues to grow. Our sales effectiveness is also improving. Our ability to actually bring Pheno into the overall bloodstream infection portfolio with BD, that we're getting much, much better at that as well. As a result, what we're seeing is we're really starting to advance sales opportunities quicker. Where, we're in labs with, you know, that are BD shops within, within the hospital, I mean, we're advancing these opportunities much, much quicker. This is work in progress that we continue to make progress on every day, and we expect to see, again, continued good success there. The last thing I'd mention is, you know, really our financial strength as a company. That's something David and I focus on frequently every day. We now have debt restructuring behind us. We're focused on reducing our burn rate. We're focused on preserving cash, everywhere we can, and then obviously, revenues will, will take care of that as well as we continue to increase revenues and, and, drop margin to the bottom line. With that, more to come, and I appreciate you tuning into the Q2 earnings call today. Again, should you have any further questions, please contact us at axdx.com, and we're happy to schedule a follow-on meeting. Thank you very much. The conference is now concluded. Thank you for attending today's presentation, and you may now disconnect.